Articles related to CLINICAL TRIALS

A recent study on bipolar I depression patients found that extended antidepressant maintenance for 52 weeks did not significantly prevent mood episode relapses compared to an 8-week regimen.

The MIRASOL trial has unveiled mirvetuximab soravtansine’s potential to revolutionize the treatment landscape for patients with platinum-resistant ovarian cancer. Physicians are invited to delve into the data that positions this novel therapy as a potential new standard of care.

The KEYNOTE-789 study results have sparked a debate on the role of immunotherapy in treating stage IV EGFR-mutated NSCLC. While the study did not show a significant benefit of adding pembrolizumab to chemotherapy, experts agree that the potential role of immunotherapy, particularly in combination with anti-angiogenic therapy, should not be completely dismissed.

Investigating a new frontier in hypertension treatment, this phase 1 study elucidates the efficacy and safety of zilebesiran, an RNA interference therapeutic agent. The study offers insights into dose-dependent effects and coadministration with existing hypertension medications, inviting further exploration in this vital area of medicine.

In a recent phase 2 trial involving patients with narcolepsy type 1, oral orexin receptor 2-selective agonist TAK-994 exhibited promising results in improving sleep latency and reducing cataplexy. However, the study was terminated early due to hepatotoxic effects, underscoring the need for further evaluation and refinement of the treatment approach.

The preliminary findings suggest a potential new direction for managing chronic pain in PTSD, inviting further research and consideration in the clinical field.